Milestone Ratchets: How Tranched Rounds Reprice You
How tranched VC rounds with milestone conditions can reprice your startup after signing, and what to negotiate before you accept the structure.
That is where many financings stop being a clean price and start becoming a contingent repricing mechanism.
On paper, a tranched round can look founder-friendly. Instead of forcing investors to price today all the execution risk around product delivery, commercial traction, key hires, or regulatory approval, the deal “splits the difference.” The first tranche closes now. The second closes once the company proves something. Everyone gets comfortable. Everyone claims alignment. The headline valuation survives.
But in practice, milestone-based financings often do something much less benign: they preserve valuation optics while shifting real pricing power into the future, usually into the hands of the investor-controlled board or investor consent rights. The company thinks it signed a $40 million pre-money round. What it may actually have signed is $15 million now at $40 million, plus an investor option to re-underwrite the rest later under conditions they can influence.
That difference is not semantic. It affects dilution, runway, leverage, control, hiring pace, customer commitments, and whether management spends the next six months building the company or litigating what “commercial launch” was supposed to mean.
This is the milestone ratchet trap: a structure that quietly reprices your startup after signing, without always calling it a repricing.
The real problem with tranched rounds
Tranched financings are not inherently abusive. In some sectors, they are rational.
Biotech financings often tie capital to trial progress or regulatory steps because the underlying risk changes dramatically at known inflection points. Hardware companies may need staged capital around manufacturing validation. Climate or deep-tech companies may need financing gates linked to plant readiness or certification. In difficult markets, staging can bridge valuation gaps that would otherwise kill a round.
The problem is not the existence of milestones. The problem is who controls whether those milestones were achieved, how much discretion exists when reality is messy, and what happens economically if the company lands near the target instead of exactly on it.
Most founders focus on the visible parts of a financing:
In a tranched round, those are only half the story. The hidden half lives in clauses like:
Those clauses can transform a committed financing into a staged call option for the investor. They get initial exposure. They preserve upside if things go well. If things go less well, they can delay, reprice, reduce, restructure, or decline the later capital while keeping the company boxed in.
Founders often miss the asymmetry. A milestone tranche is sold as risk sharing. In weak drafting, it is really downside transfer.
Why current founder approaches fail
Founders usually make four mistakes when evaluating milestone-based closings.
1. They anchor on the headline valuation
If a lead says, “We’ll do the deal at $50 million pre, but only fund half now and half after hitting $2 million ARR,” many founders compare that to a clean $35 million pre-money offer and think they won.
Maybe they did. But only if the second half is truly committed on objective terms.
If the second tranche is uncertain, then the relevant comparison is not “$50 million vs. $35 million.” It is:
A high nominal price with deferred and discretionary capital can be economically worse than a lower-priced round with certainty.
2. They treat milestones as operational, not legal
Founders think in plain English. Documents operate in adversarial English.
“Launch the product” sounds obvious until lawyers ask:
The investor does not need to prove the company failed in a colloquial sense. They only need enough contractual ambiguity to argue the trigger has not been satisfied.
3. They underestimate board and consent leverage
Suppose the company has one founder CEO, one investor director from the new lead, one existing investor, and one independent. The second tranche requires either board approval or investor majority consent that milestones were achieved. Even if the legal language looks objective, the practical reality is political.
If the lead wants to slow deployment, revisit plan, replace management, demand a recap, or force a bridge note, the tranche becomes leverage. Investors know companies approaching a milestone date with 4–6 months of runway are negotiating from weakness.
4. They assume partial success will be treated reasonably
Markets are messy. Startups rarely hit milestones exactly as modeled.
Maybe the target was $3 million ARR by September 30. The company gets to $2.7 million but with lower churn and better gross margin than plan. Maybe the product shipped on time, but enterprise security certification slipped by 45 days because of a vendor bottleneck. Maybe the VP Sales hire accepted but starts after the deadline.
Founders assume sophisticated investors will evaluate the full picture. Sometimes they do. But if the documents give investors the right to be strict, they will often become strict when macro conditions worsen or portfolio reserves tighten.
Your financing structure should not depend on everyone remaining generous under stress.
The core insight: a tranche is often a pricing formula disguised as a milestone
The cleanest way to understand a milestone ratchet is this:
A tranched round is often not one financing. It is two financings, with the second one pre-negotiated only if the company performs well enough.
Investors like this because it lets them say yes to a valuation today without truly underwriting the entire risk set.
The mechanics vary, but the economic purpose is consistent:
That is why founders should analyze tranched rounds as a set of embedded options:
This asymmetry is the trap.
How the hidden economics work
Let’s walk through actual structures.
Structure 1: Pure milestone-gated second closing
Term sheet headline
- GA launch of platform with three enterprise reference customers, or
- $250,000 MRR for two consecutive months
At first glance, this looks like a $20 million round at a $40 million pre.
But the company only has $8 million of certainty.
If the post-money on first close is treated as proportional to the tranche, the immediate issued equity is based on the amount funded. Simplify the cap table:
If the second tranche closes on the same price, investors buy another 3,000,000 shares and end at 33.3% of the company post-round.
That is what founders model.
But if the board later says the milestone was not met, the company may face three ugly alternatives:
Now run the repricing case.
Suppose the company has 5 months of cash left. Market sentiment weakens. Investors agree to fund the remaining $12 million, but now at a $24 million pre-money because the revenue trigger was missed.
New math:
The founder thought this was a 33.3% dilution round. It became a 44.4% investor ownership outcome.
That is the milestone ratchet in plain form.
Structure 2: Automatic valuation step-down if milestone is missed
Some documents are more explicit.
Example:
This is cleaner because at least the repricing formula is known. But it still embeds severe downside.
Assume 9,000,000 pre-money shares.
If company fully hits milestone:
If company partially misses and gets 80% pricing:
If company misses badly and price drops to 60%:
A founder may look at that and say, “Only a few more points of dilution.” But that understates the damage because the company also likely reaches the trigger date with less cash, weaker leverage, and possibly broader governance concessions attached.
Structure 3: Milestone plus investor drawdown veto
A subtler version is common in uncertain markets:
- no material adverse change
- compliance with covenants
- certification by board
- no breach of representations
- minimum cash management standards
This starts looking less like equity and more like a venture debt covenant package hidden inside preferred stock.
Here’s the issue: even if the company achieves the milestone, investors can use MAC language or covenant compliance to delay funding.
Examples:
None of these necessarily changes the investment case. But with broad veto rights, they become bargaining chips.
Structure 4: “Good faith renegotiation” on partial misses
This is the worst drafting of all because it creates maximum ambiguity exactly when leverage is weakest.
Example language:
> If the Milestone is not achieved by December 31, the parties shall negotiate in good faith regarding the terms of the subsequent closing, taking into account the Company’s progress and market conditions.
That is not protection. That is an invitation to a hostage negotiation.
A company with 3 months of runway and no guaranteed capital has no meaningful negotiating leverage, no matter what “good faith” says.
The milestone definitions that create trouble
Not all milestones are equally dangerous. The riskiest are those that are either manipulable, partly outside management control, or require subjective judgment.
Product milestones
Dangerous formulations:
Safer formulations use objective tests:
Revenue milestones
Dangerous formulations:
Safer formulations define:
Hiring milestones
Dangerous formulations:
That last phrase is poison. It gives investors de facto hiring approval.
Safer formulations:
Regulatory milestones
These are often the hardest because timing can sit partly outside the company’s control.
Dangerous formulations:
Safer formulations may tie milestones to company-controlled deliverables:
If the investor insists on approval-based triggers, founders should demand automatic deadline extensions for regulator-caused delays not resulting from company deficiency.
Board discretion is where economics become control
A tranche can be objectively drafted and still dangerous if the board decides whether the objective facts count.
Imagine a 5-person board after the first close:
Second tranche requires board determination that milestones were met and that release of funds is in the company’s best interest.
That “best interest” language is a quiet power transfer.
Suppose the lead believes growth is slower than expected and wants the company to cut burn, replace the CEO, and accept a recap. Even if the milestone is technically met, the board can argue that releasing more capital into the current plan is not prudent.
This is how a financing term turns into a governance weapon.
Founders should separate two questions:
If the answer to #2 is yes, you do not have committed capital. You have conditional investor discretion.
What partial misses really look like
The most common scenario is not total failure. It is close but imperfect execution.
Let’s model one.
Scenario: ARR milestone with partial miss
Terms:
- fund at 75% of original price, or
- fund half the tranche at original price and revisit the rest in 90 days
Cap table at first close:
Case A: full hit
Case B: partial miss, 75% price
Case C: investors fund only half second tranche now
Case C is often worse than an explicit repricing because it preserves ongoing leverage. Investors can drip-feed enough capital to avoid collapse while maintaining maximum negotiating power.
Why investors like tranched equity in weak markets
To be fair, investors are not irrational villains here. Tranched structures became more common whenever markets turned volatile because they solve real investor problems:
The issue is that investors often describe tranched rounds as an alignment tool when, economically, they are also a risk repricing tool.
If an investor truly wants alignment, the terms should make later funding automatic upon objective events and should limit their ability to use unrelated governance or market changes to revisit economics.
If they resist that, you have your answer: the structure is meant to preserve optionality, not just alignment.
Negotiation tactics founders should use
If you cannot avoid a tranched structure, negotiate it like a hostile document, not a trust exercise.
1. Make milestones objective, binary, and evidentiary
Every milestone should answer:
Bad:
Better:
Bad:
Better:
2. Require automatic funding triggers
The strongest clause is simple:
> Upon certification by the Company’s CFO, accompanied by supporting materials specified in the financing documents, that the Milestone has been achieved, the second tranche shall automatically close within five business days.
Not “may close.” Not “subject to investor approval.” Not “subject to board confirmation.”
If investors insist on verification rights, make them narrow:
3. Eliminate or narrow board discretion
Do not allow “board determines in good faith whether milestone satisfied.” Replace with objective verification.
If some board role is unavoidable, limit it:
4. Cap downside pricing adjustments
If valuation step-downs are unavoidable, negotiate hard boundaries.
Example:
These downside caps matter because they prevent a near-miss from turning into punitive dilution.
5. Create partial achievement schedules instead of investor election rights
Do not leave partial misses to “mutual agreement” or investor choice.
Bad:
Better:
The point is to replace discretion with formula.
6. Add automatic extensions for non-company-caused delays
If milestones depend partly on customers, regulators, vendors, or counterparties, require extension mechanics.
Examples:
7. Prevent MAC clauses from swallowing the commitment
If the second tranche is supposed to be committed, then “no material adverse change” should either be removed or defined extremely narrowly.
Otherwise the investor can override objective milestone completion with subjective deterioration claims.
At minimum:
8. Lock governance during the tranche period
Investors often combine tranched funding with governance creep:
That is backwards. If all capital is not yet fully committed, governance should not fully transfer.
Negotiate:
9. Include company optionality if investors do not fund
If investors fail to fund a tranche despite milestone achievement, the company should not remain trapped.
Add provisions such as:
Without consequences, investors can delay with little cost.
A model negotiation scenario
Suppose you receive this offer:
Investor proposal
Founder response should be direct:
“We understand you want to stage risk. But we are not going to sign a structure where half the capital is effectively unpriced.”
“Second close should be automatic upon objective milestone certification, not board approval.”
FDA clearance and ARR are different risk vectors. If either works, define exactly what counts.
“If clearance is pending because of agency review after accepted filing, tranche still funds on schedule. If ARR lands between $3.2 million and $4.0 million, second tranche funds at not less than 90% of original price.”
“No revision below a fixed floor. Alternatively, split the remainder into equity plus venture debt or a SAFE sidecar with capped dilution.”
“No additional investor board seat or expanded veto package until full round funded.”
A plausible founder-protective revised structure:
- same price equity if FDA clearance or $4.0 million ARR reached, or
- 24-month venture debt / convertible sidecar under pre-agreed terms
That is still a staged financing, but it is no longer a hidden repricing machine.
Alternatives to tranched equity when markets are uncertain
Many founders accept bad tranche terms because they assume the alternative is no deal. That is often false. There are cleaner ways to bridge valuation disagreement.
1. Smaller clean equity round
Raise less now at a price everyone can actually underwrite. Yes, it may mean lower proceeds. But certainty often beats a larger fictional round.
A clean $10 million round at a slightly lower valuation can be better than a $20 million tranched round where half the capital is discretionary.
2. Uncapped or lightly capped SAFE sidecar from insiders
If the issue is short-term proof points, insiders may provide bridge capital via SAFE or note while the company reaches the next milestone. This is especially useful if the lead likes the company but does not want to size the full check today.
The key is ensuring the bridge does not stack punitive discounts, valuation caps, MFN rights, and shadow preferred terms all at once.
3. Venture debt after an initial clean equity close
If the delayed capital is really runway insurance rather than risk capital, debt may be more honest. Debt has its own hazards, but at least it does not pretend to preserve valuation while quietly reserving repricing rights.
4. Warrants instead of ratchets
Sometimes investors want extra upside for taking early risk. A warrant package can be cleaner than future repricing discretion. Founders may dislike it, but at least the economics are visible upfront.
5. Pre-agreed extension financing
Rather than a milestone-gated second tranche, negotiate a company option to sell additional preferred at a fixed price within a set period. The investor can agree upfront to backstop some or all of it. This preserves financing flexibility without tying funding to subjective milestone debates.
The founder rule: price certainty beats valuation theater
The hardest thing for founders to admit is that a round can have a great valuation and still be a bad financing.
A tranched round with discretionary funding is often exactly that. It gives you the optics of success and the economics of conditional approval. It lets investors say yes without fully saying yes.
Founders should ask one blunt question whenever a tranche appears:
“If we perform reasonably well but not perfectly, who gets to decide what happens next?”
If the answer is “the investor,” then your valuation is probably not real.
Real valuation means capital is committed on defined terms. Real alignment means milestones are objective and automatic. Real downside sharing means misses produce bounded consequences, not open-ended renegotiation.
Anything else is usually a ratchet with better branding.
Takeaways
The right founder posture is not ideological opposition to tranched financing. It is precision. If investors want staging, fine. But staging must not become a silent transfer of pricing power after the term sheet is signed.
Because once runway shortens, “alignment” has a way of turning into repricing.
RaiseSimpli Team
Author